Epidemiologiske undersøgelser af risikoen for teratogenitet ved behandling med ACE- hæmmere under graviditetens første trimester er inkonklusive, men en lille forøget risiko kan ikke udelukkes.
Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded.